Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

By S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F. Locke, K. Komanduri, Yi Lin, N. Jain, N. Daver and 9 more. Nature Reviews Clinical Oncology, 2018

2,143 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/c9c525f90d74beaa39b7ae7ae098610ab3b1504e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Neurology

T. Hirano

In Oncology

Citations in the corpus

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018, background): “Nonconvulsive status epilepticus (NCSE) has been reported with CD19 CAR T-cell therapy (17), and we found EEG evidence of NCSE in 2 patients, both of whom also had a clinical seizure.”
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, methodology): “The CARTOX consensus group have published a grading system for CAR T-cell neurologic toxicity [43].”
IL-6 in inflammation, autoimmunity and cancer (2020, background): “It is triggered by the activation of CAR-T cells that recognize cognate antigens expressed by tumor cells, leading to the release of cytokines and chemokines, including IL-6 in parallel with the release of pro-inflammatory cytokines and chemokines by monocytes and/ or macrophages (351, 352).”
Cytokine release syndrome (2018, background): “The management of CRS follows a grade- and riskadapted strategy for monitoring and therapy [28, 29].”
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells (2018, background): “The term CAR-related encephalopathy syndrome (CRES) has been proposed to describe neurotoxicity associated with CAR T cell therapy [12].”
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome (2020, positive): “Considering that the anti-IL-6R antibody tocilizumab is an effective treatment for CRS in CAR-T cell therapies (Neelapu et al., 2018) , researchers might want to consider drugs with a similar mechanism of action for CRS in COVID-19.”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, methodology): “Transcription activator-like (TAL) effector nuclease (TALEN) technologies have also been used to knockout the TCR 232 , and TALEN-edited anti-CD19 CAR T cells have induced remissions in infants with B cell ALL, with no GVHD observed 233 .”